Quantcast

Rockville’s Vanda Pharmaceuticals reports 2Q loss of $1.3M

Vanda Pharmaceuticals Inc. of Rockville reported a second-quarter net loss of $1.3 million, or 5 cents per diluted share, on revenue of $7.4 million, versus net income of $1.3 million, or 4 cents per diluted share, on revenue of $8.3 million for the year-ago period.

Analysts on average expected a loss of 5 cents per share.

The company, which develops drugs to treat central nervous system disorders, said lower royalty payments related to its flagship drug, Fanapt, a schizophrenia treatment, hit its bottom line hard, as did higher research and development expenses and the ongoing cost of clinical trials.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

 

[index]
[index]
[i]
[i]
[id, count]
[id, count]
[f.tagName.toLowerCase()]
[f.tagName.toLowerCase()]
[id, validationType, arg1, arg2]
[id, validationType, arg1, arg2]
[field.tagName.toLowerCase()]
[field.tagName.toLowerCase()]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]